Anti-smoking medication shows promise for treating alcohol dependence

June 4, 2013

A smoking-cessation medication may be a viable option for the treatment of alcohol dependence, according to a study by scientists at the National Institutes of Health. The study found that varenicline (marketed under the name Chantix), approved in 2006 to help people stop smoking, significantly reduced alcohol consumption and craving among people who are alcohol-dependent. The findings were published online in the Journal of Addiction Medicine.

"This is an encouraging development in our effort to expand and improve treatment options for people with ," says Kenneth R. Warren, Ph.D., acting director of the National Institute on and Alcoholism (NIAAA), part of NIH. "Current medications for alcohol dependence are effective for some, but not all, patients. New medications are needed to provide effective therapy to a broader spectrum of alcohol dependent individuals."

Alcohol dependence is a chronic disease that includes symptoms such as craving, loss of control over drinking, withdrawal symptoms after stopping drinking, and tolerance, the need to drink greater amounts of alcohol to feel the same effect.

"Drinking and smoking often co-occur, and given their genetic and neurochemical similarities, it is perhaps unsurprising that a treatment might serve to treat alcohol problems," notes lead author Raye Z. Litten, Ph.D., associate director of the NIAAA Division of Treatment and Recovery Research. "Our study is the first multi-site clinical trial to test the effectiveness and safety of varenicline in a population of smokers and nonsmokers with alcohol dependence," said Dr. Litten.

Early studies testing varenicline as a suggested it might also be effective for treating alcohol problems. Varenicline works by partially stimulating receptors for nicotinic acetylcholine, a promising molecular target implicated in both nicotine and . This hypothesis was supported by early animal studies which showed that varenicline decreases .

Dr. Litten and NIAAA colleagues Dr. Joanne Fertig, Dr. Daniel Falk and Megan Ryan worked with NIAAA's Clinical investigations Group, a multi-center team of researchers at Boston Medical Center; the University of Virginia, Charlottesville; Dartmouth University, Hanover, N.H.; the University of Pennsylvania, Philadelphia; and Johns Hopkins University School of Medicine, Baltimore. The researchers randomized 200 alcohol-dependent adults to receive varenicline or placebo each day for 13 weeks.

Study participants had reported drinking an average of at least 28 drinks per week for females or 35 drinks per week for males prior to the study, with women and men drinking at least four and five drinks, respectively, on most days.

Compared with placebo, varenicline significantly reduced measures of alcohol use. For example, the percentage of heavy drinking days per week decreased nearly 22 percent in the varenicline group.

The researchers noted that varenicline's effects were comparable to those seen in studies of naltrexone and acamprosate, two of the medications already approved by the U.S. Food and Drug Administration for the treatment of alcohol dependence. The average treatment effect on alcohol use was similar for smokers and nonsmokers. Alcohol craving also was significantly reduced in people treated with varenicline.

Dr. Litten and colleagues reported that varenicline was well-tolerated by study participants. The most common side-effects of varenicline were nausea, abnormal dreams, and constipation, and those effects generally were mild. The researchers conclude that longer treatment with and follow-up assessments to determine if there are sustained effects would be a valuable next step in the development of this medication for .

Explore further: Smoking cessation aide shows promise as alcoholism treatment

More information: Litten, R. et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence, Journal of Addiction Medicine, 2013 May 31.

Related Stories

Smoking cessation aide shows promise as alcoholism treatment

February 15, 2012
A medication commonly used to help people stop smoking may have an unanticipated positive side effect for an entirely different vice: drinking alcohol. A new study by University of Chicago researchers finds that varenicline, ...

Anti-smoking drug decreases alcohol consumption in heavy-drinking smokers

May 3, 2012
The smoking cessation drug varenicline significantly reduced alcohol consumption in a group of heavy-drinking smokers, in a study carried out by researchers at the Ernest Gallo Clinic and Research Center at the University ...

Self-medicating with alcohol linked to later dependence

May 5, 2013
(HealthDay)—Use of alcohol to self-medicate mood symptoms correlates with increased odds of subsequent alcohol dependence and persistence of dependence, according to a study published online May 1 in JAMA Psychiatry.

Quitting smoking: Licensed medications are effective

May 30, 2013
Nicotine replacement therapy and other licensed drugs can help people quit smoking, according to a new systematic review published in The Cochrane Library. The study, which is an overview of previous Cochrane reviews, supports ...

A new treatment option for alcohol dependence: Reduced consumption rather than abstinence

April 11, 2013
A potential new treatment for alcoholism called nalmefene is effective and safe for reducing alcohol consumption in alcohol dependent individuals, says a new study published this week in Biological Psychiatry.

Recommended for you

Incorporating 12-step program elements improves youth substance-use disorder treatment

July 26, 2017
A treatment program for adolescents with substance-use disorder that incorporates the practices and philosophy of 12-step programs like Alcoholics Anonymous (AA) produced even better results than the current state-of-the ...

Concern with potential rise in super-potent cannabis concentrates

July 21, 2017
University of Queensland researchers are concerned the recent legalisation of medicinal cannabis in Australia may give rise to super-potent cannabis concentrates with associated harmful effects.

Findings link aldosterone with alcohol use disorder

July 18, 2017
A new study led by scientists at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, demonstrates that aldosterone, a hormone produced in the adrenal glands, may contribute ...

Depression among young teens linked to cannabis use at 18

July 17, 2017
A study looking at the cumulative effects of depression in youth, found that young people with chronic or severe forms of depression were at elevated risk for developing a problem with cannabis in later adolescence.

Why does prenatal alcohol exposure increase the likelihood of addiction?

July 7, 2017
One of the many negative consequences when fetuses are exposed to alcohol in the womb is an increased risk for drug addiction later in life. Neuroscientists in the University at Buffalo Research Institute on Addictions are ...

Researchers say U.S. policies on drugs and addiction could use a dose of neuroscience

June 23, 2017
Tens of thousands of Americans die from drug overdoses every year – around 50,000 in 2015 – and the number has been steadily climbing for at least the last decade and a half, according to the National Institute on Drug ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.